Dabrafenib is an oral BRAF kinase inhibitor approved for the treatment of various BRAF V600 mutation-positive solid tumors. In vitro observations suggesting cytochrome P450 (CYP) 3A induction and organic anion transporting polypeptide (OATP) inhibition prompted us to evaluate the effect of dabrafenib 150 mg twice daily on the pharmacokinetics of midazolam 3 mg (CYP3A substrate) and rosuvastatin 10 mg (OATP1B1/1B3 substrate) in a clinical phase 1, open-label, fixed-sequence study in patients with BRAF V600 mutation-positive tumors. Repeat dabrafenib dosing resulted in a 2.56-fold increase in rosuvastatin maximum observed concentration (C ), an earlier time to C , but only a 7% increase in area under the concentration-time curve from time 0 (predose) extrapolated to infinite time. Midazolam C and AUC extrapolated to infinite time decreased by 47% and 65%, respectively, with little effect on time to C . No new safety findings were reported. Exposure of drugs that are CYP3A4 substrates is likely to decrease when coadministered with dabrafenib. Concentrations of medicinal products that are sensitive OATP1B1/1B3 substrates may increase during the absorption phase.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453865 | PMC |
| http://dx.doi.org/10.1002/cpdd.937 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endogenous plasma riboflavin is not a viable BCRP biomarker in human.
Clin Transl Sci
December 2024
Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co-administration of 375 mg once daily (q.
View Article and Find Full Text PDFClinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.
Clin Transl Sci
April 2024
GSK, Collegeville, Pennsylvania, USA.
Article Synopsis
- Momelotinib, an approved treatment for myelofibrosis in adults with anemia, was studied for drug-drug interactions (DDIs) with different inhibitors and inducers affecting its metabolism, specifically looking at the impact of medications like ritonavir and rifampin.
- The study found that while coadministration with ritonavir and rifampin did increase momelotinib and its metabolite M21 exposure, these changes were not clinically significant.
- Momelotinib did not impact the metabolism of certain drugs, but it significantly altered the levels of rosuvastatin, indicating that monitoring and possible dose adjustments may be necessary for patients taking these medications together.
Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function.
Clin Pharmacol Ther
July 2023
Department of Surgery, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Realistic models predicting hepatobiliary processes in health and disease are lacking. We therefore aimed to develop a physiologically relevant human liver model consisting of normothermic machine perfusion (NMP) of explanted diseased human livers that can assess hepatic extraction, clearance, biliary excretion, and drug-drug interaction (DDI). Eleven livers were included in the study, seven with a cirrhotic and four with a noncirrhotic disease background.
View Article and Find Full Text PDFP-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
J Clin Pharmacol
February 2023
Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
This study evaluates the influence of pregnancy and HIV infection in conjunction with the use of raltegravir, lamivudine, and tenofovir disoproxil fumarate (combined antiretroviral therapy [cART]) on intestinal P-glycoprotein (P-gp) and hepatic organic anion transporter polypeptide (OATP) 1B1/1B3 and/or breast cancer resistance protein (BCRP) drug transporter activity using rosuvastatin (OATP1B/BCRP) and fexofenadine (P-gp) probes. Single oral doses of 5-mg rosuvastatin and 60-mg fexofenadine were administered to women living with HIV under cART in the third trimester of gestation (n = 15) and postpartum period (n = 10). A control group of 12 healthy nonpregnant women also was investigated.
View Article and Find Full Text PDFResults From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Eur J Drug Metab Pharmacokinet
November 2022
Chrestos Concept GmbH & Co. KG, 45131, Essen, Germany.
Background And Objectives: In vitro and in vivo studies were performed with the novel, selective, nonsteroidal mineralocorticoid receptor antagonist finerenone to assess the relevance of inhibitory effects on the transporters breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), and OATP1B3. These transporters are involved in the disposition of a number of drugs, including statins. Statins are also a frequent comedication in patients receiving finerenone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!